This page shows the latest Infinity Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Bristol-Myers Squibb and Infinity Pharmaceuticals have teamed up to study tumour resistance to checkpoint inhibitors in BMS' immuno-oncology drug Opdivo (nivolumab). ... Our agreement with Infinity builds on our continued focus to bring forward potential
Its nearest competitor is Infinity Pharmaceuticals' IPI145 which is in phase II trials.
last month - although another candidate from Infinity Pharmaceuticals' called IPI145 has shown early promise in phase I dose-ranging studies and is now in phase II.
One HSP90 inhibitor, retaspimycin (IPI-504, Infinity Pharmaceuticals), advanced into phase III clinical trials in GIST patients pre-treated with at least imatinib and sunitinib; however, this trial (RING trial) had ... Krystexxa (Savient Pharmaceuticals).
Licenser/Partner or Acquirer. Product/Technology. Development status. Headline ($m). Arena Pharmaceuticals/Eisai. ... 508. Intellikine/Infinity Pharmaceuticals. INK1197 and other PI3K inhibitors – inflammation/oncology. Preclinical .
Novartis and Infinity in cancer drug deal. US biotech firm, Infinity Pharmaceuticals, has signed a deal worth up to $400m with Novartis to develop cancer treatments. ... Total payments could reach $400m if Infinity meets certain milestones related to
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Licensor Acquired/ Licensee Acquirer. Product/ Technology. Deal Type. Headline ($m). Selexys Pharmaceuticals/ Novartis. ... development and commercialisation. 45. Infinity Pharmaceuticals/ Verastem. Duvelisib, oral inhibitor of PI3K‐delta and
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
He has also served as vice president, business and corporate development at Infinity Pharmaceuticals, where he was responsible for the company’s in-licensing, out-licensing and alliance management activities.
Prior to this, Keilty served as vice president of information technology and informatics at Infinity Pharmaceuticals, and held a number of positions at Millennium Pharmaceuticals working with the company's core
Prior to Biogen, he founded Infinity Pharmaceuticals, and served as its chief executive officer and chairman of the board of directors. ... During his 30 years of biotech industry experience, Holtzman also served as the chief business officer at
Executive VP of Infinity Pharmaceuticals joins the team. Ardelyx has appointed William Bertrand Jr to its board of directors. ... Bertrand is currently executive VP of general counsel for Infinity Pharmaceuticals and prior to this he served as senior VP
Dr Nichols joins as chief operating officer from Resolvyx Pharmaceuticals, where he was president and chief operating officer. ... Dr Adams is president of R&D at Infinity Pharmaceuticals having served at Millennium Pharmaceuticals, where he had global
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...